- Home
- USIO vs ATOS Comparison
USIO vs ATOS Comparison
Compare USIO & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | USIO | ATOS |
|---|---|---|
| Founded | 1998 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.0M | 36.2M |
| IPO Year | 1999 | 2010 |
Fundamental Metrics
Financial Performance| Metric | USIO | ATOS |
|---|---|---|
| Price | $1.14 | $4.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $4.00 | ★ $28.33 |
| AVG Volume (30 Days) | 56.7K | ★ 81.7K |
| Earning Date | 03-18-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $28,200,535.00 | $1,758.00 |
| Revenue This Year | $15.47 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 12.69 | N/A |
| 52 Week Low | $1.03 | $0.53 |
| 52 Week High | $2.02 | $7.56 |
Technical Indicators
Market Signals| Indicator | USIO | ATOS |
|---|---|---|
| Relative Strength Index (RSI) | 36.18 | 49.61 |
| Support Level | $1.03 | $3.80 |
| Resistance Level | $1.42 | $5.12 |
| Average True Range (ATR) | 0.07 | 0.47 |
| MACD | -0.01 | -0.13 |
| Stochastic Oscillator | 35.71 | 6.00 |
Price Performance
Historical ComparisonAbout USIO Usio Inc.
Usio Inc is a United States-based company that provides integrated electronic payment services, including credit and debit card-based processing services and transaction processing via the Automated Clearing House, or ACH network to billers and retailers. The Company also has an additional wholly-owned subsidiary, which is the entity for Output Solutions operations.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.